Friström B, Nilsson S E
Department of Ophthalmology, University of Linköping, Sweden.
Arch Ophthalmol. 1993 May;111(5):662-5. doi: 10.1001/archopht.1993.01090050096037.
To evaluate the effects of PhXA41, a new prostaglandin analogue, on the intraocular pressure (IOP) in patients receiving pilocarpine treatment and the effects of pilocarpine in patients receiving PhXA41 treatment.
Twenty patients with ocular hypertension were randomized into two parallel groups. The treatment period was 2 weeks. Ten patients in group 1 were given PhXA41 twice daily during week 1 and, in addition, pilocarpine three times daily during week 2. Ten patients in group 2 received pilocarpine three times daily during week 1 and PhXA41 twice daily in addition during week 2. PhXA41 was used in a concentration of 0.006%, and pilocarpine was given in a concentration of 2%.
In group 1, the mean IOP on day 0 was 25.1 mm Hg; on day 7, 19.1 mm Hg; and on day 14, 17.6 mm Hg. In group 2, the mean IOP on day 0 was 23.8 mm Hg; on day 7, 20.4 mm Hg; and on day 14, 17.7 mm Hg.
PhXA41 had a clinically significant IOP-lowering effect (23.4% reduction on day 7 as compared with baseline day (P < .001). The corresponding value with pilocarpine was 14.3% (P < .001). When pilocarpine was added to PhXA41, the additional IOP reduction was 7.4% (P < .01) compared with 14.2% (P < .01) when PhXA41 was added to pilocarpine. The two groups were found to have an almost equal reduction in IOP on day 14 (group 1, 29.4%; group 2, 26.6%). No serious adverse reactions were seen. Some conjunctival hyperemia in the PhXA41-treated eyes was noted on day 7, as compared with the pilocarpine-treated eyes, but there were few complaints of discomfort.
This study indicated that PhXA41 could be useful in the treatment of glaucoma, as monotherapy, or in certain cases in combination with pilocarpine.
评估新型前列腺素类似物PhXA41对接受毛果芸香碱治疗患者的眼压（IOP）的影响，以及毛果芸香碱对接受PhXA41治疗患者的影响。
20例高眼压患者被随机分为两个平行组。治疗期为2周。第1组的10例患者在第1周每天使用PhXA41两次，此外，在第2周每天使用毛果芸香碱三次。第2组的10例患者在第1周每天使用毛果芸香碱三次，在第2周每天额外使用PhXA41两次。PhXA41的使用浓度为0.006%，毛果芸香碱的使用浓度为2%。
在第1组中，第0天的平均眼压为25.1 mmHg；第7天为19.1 mmHg；第14天为17.6 mmHg。在第2组中，第0天的平均眼压为23.8 mmHg；第7天为20.4 mmHg；第14天为17.7 mmHg。
PhXA41具有显著的降低眼压作用（与基线日相比，第7天降低了23.4%，P <.001）。毛果芸香碱的相应值为14.3%（P <.001）。当在PhXA41基础上加用毛果芸香碱时，眼压额外降低7.4%（P <.01），而在毛果芸香碱基础上加用PhXA41时，眼压额外降低14.2%（P <.01）。发现两组在第14天的眼压降低幅度几乎相等（第1组为29.4%；第2组为26.6%）。未观察到严重不良反应。与毛果芸香碱治疗的眼睛相比，在第7天观察到PhXA41治疗的眼睛有一些结膜充血，但很少有不适主诉。
本研究表明，PhXA41作为单一疗法或在某些情况下与毛果芸香碱联合使用，可能对青光眼治疗有用。
